Welcome to our dedicated page for Glaukos SEC filings (Ticker: GKOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Glaukos Corporation filings document the regulatory record for an ophthalmic pharmaceutical and medical technology company with common stock listed on the New York Stock Exchange under GKOS. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary net sales information, supplemental business summaries, and Regulation FD investor presentations.
The company’s proxy materials provide governance and executive-compensation disclosures, including equity-award and pay-versus-performance information. These filings also identify Glaukos as a Delaware corporation and frame disclosure around its glaucoma, corneal-disorder, and retinal-disease therapies, commercial products, risk disclosures, and public-company reporting obligations.
Glaukos Corporation director Aimee S. Weisner reported receiving a grant of 623 shares of common stock on January 2, 2026. According to the disclosure, this represents a grant of restricted stock units under Glaukos’ Director Compensation Policy, which will vest in full on the one-year anniversary of the grant date and be settled in an equal number of common shares.
After this grant, Weisner beneficially owns 19,786 shares of common stock directly, which includes 2,731 restricted stock units that have not yet vested or been delivered, as well as vested units for which delivery has been deferred. She also reports indirect holdings of 28,525 shares through the Saeman-Weisner Family Trust and 2,000 shares through the Weisner Saeman Family Irrevocable Trust.
Glaukos Corporation director Denice Torres reported receiving a new equity grant. On January 2, 2026, she was awarded 623 shares of Glaukos common stock at a price of $0 per share, reflecting a grant of restricted stock units under the company’s Director Compensation Policy. These units will vest in full on the one-year anniversary of the grant date and will be settled in the same number of common shares.
After this grant, Torres beneficially owns 22,334 shares of Glaukos common stock, including 2,731 restricted stock units that have not yet vested or been delivered. The filing classifies her holdings as directly owned and confirms her role as a director, with no indication that she is a 10% owner or an officer of the company.
Glaukos Corp director Gilbert H. Kliman reported an equity grant of 623 restricted stock units on January 2, 2026. The award was made under the company’s Director Compensation Policy at a grant price of $0 per share. These units will vest in full on the one-year anniversary of the grant date and will be settled in the same number of Glaukos common shares. Following this grant, Kliman beneficially owns 35,528 shares of common stock, which includes 2,731 restricted stock units that have not yet vested or been delivered, as well as vested units for which delivery has been deferred.
Glaukos Corporation director Mark J. Foley reported an equity award in the form of restricted stock units. On 01/02/2026, he received 1,168 restricted stock units of Glaukos common stock at a stated price of $0 per share under the company’s Director Compensation Policy. These units will vest in full on the one-year anniversary of the grant date and are then payable in an equivalent number of Glaukos common shares.
Following this grant, Foley beneficially owns 58,389 shares of common stock, which the disclosure notes includes 3,276 restricted stock units that have not yet vested or been delivered.
Glaukos Corporation granted director Marc Stapley 727 restricted stock units on 01/02/2026. These units were issued under the company’s Director Compensation Policy, will vest in full one year after the grant date, and will be settled in the same number of Glaukos common shares.
Following this award, Stapley beneficially owns 37,449 shares of Glaukos common stock, which includes 2,835 restricted stock units that have not yet vested or been delivered, as well as vested units whose delivery has been deferred.
Glaukos Corporation's Chief Development Officer reported a routine share withholding related to equity compensation. On 12/30/2025, 510 shares of common stock were withheld by the company at $114.24 per share to cover tax obligations when previously granted restricted stock units vested. After this transaction, the officer beneficially owned 77,451 shares of common stock. This total includes 43,562 restricted stock units that have been granted but have not yet vested or been delivered, meaning they may convert into shares over time if service or other conditions are met.
Glaukos Corporation’s Chairman, CEO and director reported an insider stock transaction dated 12/30/2025. The filing shows that 1,098 shares of common stock were withheld by the company to satisfy the reporting person’s tax withholding obligations when restricted stock units granted on March 24, 2022 vested and were delivered.
After this tax-withholding transaction, the insider beneficially owned 153,775 shares of Glaukos common stock. This total includes 89,621 restricted stock units that have been granted but have not yet vested or been delivered.
Glaukos Corporation’s chairman and CEO reported earning 4,168 shares of common stock tied to a performance-based restricted stock unit award granted on March 24, 2022. The board’s Compensation, Nominating and Governance Committee determined certain operational targets were achieved, so this portion of the award was earned at a reported price of $0 per share.
Half of these 4,168 shares are scheduled to vest and be delivered in March 2026 and the other half in December 2026. Following this transaction, 154,873 shares are beneficially owned directly, including 91,705 restricted stock units that have not yet vested or been delivered, and additional indirect holdings are reported through several Burns family and charitable trusts. The CEO also acquired 8,416 stock options at an exercise price of $55.18 per share from the same 2022 performance award, which will vest 50% in March 2026 and 50% in December 2026 and are part of 86,262 stock options held directly, expiring on March 24, 2032.
Glaukos Corp reported that its President and COO acquired 7,316 stock options on 12/11/2025 under a previously granted award tied to pre-determined operational targets. These options have an exercise price of $55.18 and were earned after the Compensation, Nominating & Governance Committee determined that certain operational targets over a multi-year performance period had been achieved.
The options represent a portion of an award originally granted on March 24, 2022, and will vest in two equal installments, with 50% becoming exercisable in March 2026 and the remaining 50% in December 2026. Following this transaction, the executive beneficially owned 65,013 derivative securities, held directly.
Glaukos Corporation disclosed that its senior vice president and chief financial officer earned 3,660 stock options tied to performance goals. These options, with an exercise price of $55.18 per share, are part of an award originally granted in March 2022 and became earned after the company met specified operational targets.
Half of this earned portion will vest and become exercisable in March 2026, with the remaining half vesting in December 2026. After this update and a de minimis correction of a prior mathematical error, the officer directly holds 37,510 stock options in total.